Promising directions in atherosclerosis treatment based on epigenetic regulation using microRNAs and long noncoding RNAs
D Skuratovskaia, M Vulf, A Komar, E Kirienkova… - Biomolecules, 2019 - mdpi.com
Atherosclerosis is one of the leading causes of mortality from cardiovascular disease (CVD)
and is a chronic inflammatory disease of the middle and large arteries caused by a …
and is a chronic inflammatory disease of the middle and large arteries caused by a …
Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for …
F Jiang, Q Hu, Z Zhang, H Li, H Li… - Journal of medicinal …, 2019 - ACS Publications
The bromodomain and extra-terminal domain (BET) family of proteins are readers which
specifically recognize histone-acetylated lysine residues. Each BET bromodomain protein …
specifically recognize histone-acetylated lysine residues. Each BET bromodomain protein …
BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST
J Mu, P Sun, Z Ma, P Sun - Cell death & disease, 2019 - nature.com
The most commonly occurring sarcoma of the soft tissue is gastrointestinal stromal tumor
(GIST). Treatment and prevention of the disease necessitate an understanding of the …
(GIST). Treatment and prevention of the disease necessitate an understanding of the …
Synthesis and biological investigation of (+)-JD1, an Organometallic BET Bromodomain Inhibitor
S Hassell-Hart, A Runcie, T Krojer, J Doyle… - …, 2019 - ACS Publications
(+)-JD1, a rationally designed ferrocene analogue of the BET bromodomain (BRD) probe
molecule (+)-JQ1, has been synthesized and evaluated in biophysical, cell-based assays as …
molecule (+)-JQ1, has been synthesized and evaluated in biophysical, cell-based assays as …
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208
P Yu, W Liu, J Ren, Y Wang, Y Ning, M Huang… - Bioorganic & Medicinal …, 2019 - Elsevier
Abstract Bromodomain-containing protein 4 (BRD4) is a new therapeutic target for the
treatment of diseases including cardiovascular diseases, cancer, inflammation and central …
treatment of diseases including cardiovascular diseases, cancer, inflammation and central …